ASACOL- mesalamine tablet, delayed release

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

MESALAMINE (UNII: 4Q81I59GXC) (mesalamine - UNII:4Q81I59GXC)

Tilgjengelig fra:

State of Florida DOH Central Pharmacy

INN (International Name):

MESALAMINE

Sammensetning:

MESALAMINE 400 mg

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. Asacol tablets are contraindicated in patients with hypersensitivity to salicylates or to any of the components of the Asacol tablet. Abuse: None reported. Dependency: Drug dependence has not been reported with chronic administration of mesalamine.

Produkt oppsummering:

Asacol tablets are available as red-brown, capsule-shaped tablets containing 400 mg mesalamine and imprinted “Asacol NE” in black. They are supplied by State of Florida DOH Central Pharmacy as follows: Store at controlled room temperature 20°- 25°C (68°- 77°F) [See USP].

Autorisasjon status:

New Drug Application

Preparatomtale

ASACOL - MESALAMINE TABLET, DELAYED RELEASE
STATE OF FLORIDA DOH CENTRAL PHARMACY
----------
AS ACOL
(MES ALAMINE)
DELAYED-RELEASE TABLETS
DESCRIPTION
Each ASACOL delayed-release tablet for oral administration contains
400 mg of mesalamine, an anti-
inflammatory drug. The ASACOL delayed-release tablets are coated with
acrylic based resin, Eudragit S
(methacrylic acid copolymer B, NF), which dissolves at pH 7 or
greater, releasing mesalamine in the
terminal ileum and beyond for topical anti-inflammatory action in the
colon. Mesalamine has the
chemical name 5-amino-2-hydroxybenzoic acid; its structural formula
is:
INACTIVE INGREDIENTS: Each tablet contains colloidal silicon dioxide,
dibutyl phthalate, edible black ink,
iron oxide red, iron oxide yellow, lactose, magnesium stearate,
methacrylic acid copolymer B (Eudragit
S), polyethylene glycol, povidone, sodium starch glycolate, and talc.
CLINICAL PHARMACOLOGY
Mesalamine is thought to be the major therapeutically active part of
the sulfasalazine molecule in the
treatment of ulcerative colitis. Sulfasalazine is converted to
equimolar amounts of sulfapyridine and
mesalamine by bacterial action in the colon. The usual oral dose of
sulfasalazine for active ulcerative
colitis is 3 to 4 grams daily in divided doses, which provides 1.2 to
1.6 grams of mesalamine to the
colon.
The mechanism of action of mesalamine (and sulfasalazine) is unknown,
but appears to be topical rather
than systemic. Mucosal production of arachidonic acid (AA)
metabolites, both through the
cyclooxygenase pathways, i.e., prostanoids, and through the
lipoxygenase pathways, i.e., leukotrienes
(LTs) and hydroxyeicosatetraenoic acids (HETEs), is increased in
patients with chronic inflammatory
bowel disease, and it is possible that mesalamine diminishes
inflammation by blocking cyclooxygenase
and inhibiting prostaglandin (PG) production in the colon.
PHARMACOKINETICS: ASACOL tablets are coated with an acrylic-based
resin that delays release of
mesalamine until it reaches the terminal ileum and beyond. T